Glatiramer

Summary

Glatiramer acetate (Copaxone) is a synthetic polypeptide immunomodulator approved for subcutaneous injection in the treatment of relapsing‑remitting multiple sclerosis (RRMS). It is used to reduce the frequency of clinical relapses and may modestly slow disability progression. The drug has been in clinical use for decades and is considered one of the first‑line disease‑modifying therapies for MS.

Mechanism of Action

Glatiramer acetate is a mixture of synthetic polypeptides composed of L-glutamic acid, L-alanine, L-tyrosine, and L-lysine in defined molar ratios. It acts as an antigen decoy by binding to MHC class II molecules and inducing T-cell anergy or shift toward anti-inflammatory Th2 regulatory cells, thereby reducing autoimmune attack on myelin in multiple sclerosis.

What the Research Shows

Systematic reviews of MS treatments list parenteral glatiramer acetate as a key disease‑modifying therapy. A 2024 Cochrane network meta‑analysis of 50 randomized trials (36,541 participants) found that glatiramer acetate produced a moderate reduction in relapse risk over 24 months (relative risk 0.84, 95% CI 0.76–0.93) with moderate‑certainty evidence. The same analysis reported a slight increase in treatment discontinuation due to adverse events (odds ratio 1.48, 95% CI 1.01–2.14). A 2024 systematic review of drug‑induced progressive multifocal leukoencephalopathy noted that glatiramer acetate has a relatively safe profile, although isolated PML cases have been reported. Overall, the evidence supports modest efficacy with a generally acceptable safety record, but long‑term data beyond two years remain limited.

Reported Benefits

Clinical trial data show glatiramer acetate modestly lowers the likelihood of relapses in RRMS, with a relative risk reduction of about 16% over two years. The drug’s safety profile is considered relatively favorable, with few serious infections reported and only rare instances of progressive multifocal leukoencephalopathy. These attributes have made it a common first‑line option for many patients.

Limitations of the Evidence

The relapse‑reducing effect of glatiramer acetate is modest compared with newer agents such as natalizumab or cladribine. Meta‑analyses indicate a slightly higher rate of discontinuation due to adverse events. Long‑term efficacy and safety beyond two years are not well established, and many trials show risk of bias, especially sponsorship‑related concerns. Rare cases of PML have been documented, highlighting a need for vigilance.

Safety Considerations

Glatiramer acetate is generally well tolerated, but occasional injection‑site reactions and systemic side effects can lead to treatment discontinuation. Network meta‑analyses suggest a modest increase in adverse‑event‑related withdrawals. Very rare cases of progressive multifocal leukoencephalopathy have been reported, underscoring the importance of monitoring for new neurological symptoms. Serious adverse events appear uncommon, but clinicians should remain alert to infection risk.

How It Is Administered

The medication is supplied as an acetate formulation for subcutaneous injection. It is administered by a healthcare professional or self‑injected under guidance. The preparation is a sterile solution intended for injection into the fatty tissue under the skin.

Routes of Administration

Goals & Uses

• Reduction of relapse rate in relapsing-remitting multiple sclerosisDisease ModificationHigh
• Relapsing‑remitting multiple sclerosisDisease Modifying TherapyHigh
• Treatment of clinically isolated syndrome (CIS)Disease ModificationModerate
• Reduction of MRI T2 lesion burdenRadiological OutcomesHigh
• Delay of disability progressionNeurological PreservationModerate

Contraindications

• Hypersensitivity to glatiramer acetate or mannitolAllergy/immunologyHigh
• Hypersensitivity to glatiramer acetateAllergyHigh

Adverse Effects

• LipoatrophyDermatologicalUncommon
• Chest painSystemicRare
• Immediate post‑injection systemic reactionsSystemicRare
• Injection site reactionsLocalCommon
• Skin necrosisDermatologicalRare
• Anxiety and depressionNeuropsychiatricUncommon
• Immediate post-injection reaction (IPIR)Systemic/cardiovascularUncommon
• LymphadenopathyLymphoreticularUncommon
• Transient flushingVasomotorCommon

Drug Interactions

• Live vaccinesHigh
• Immunosuppressants (e.g., azathioprine, methotrexate)Moderate
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• PregnancyReproductive SafetyRelative
• Renal impairmentOrgan ImpairmentRelative
• Pediatric patients (<18 years)AgeRelative
• LactationReproductiveRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: relapsing‑remitting multiple sclerosis
• United StatesApprovedApproved: relapsing‑remitting multiple sclerosis
• United KingdomApprovedApproved: relapsing‑remitting multiple sclerosis

FDA approved (1996) for relapsing‑remitting MS; also approved in the EU and UK.

Evidence & Sources

• Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis
  Journal ArticleHighRindi LV, et al.2024-01-01T00:00:00.000000Z
• Multiple sclerosis
  Journal ArticleHighNicholas R, Rashid W2012-01-01T00:00:00.000000Z
• Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
  Journal ArticleHighGonzalez-Lorenzo M, et al.2024-01-01T00:00:00.000000Z
• Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis
  Journal ArticleHighTramacere I, et al.2023-01-01T00:00:00.000000Z
• Multiple sclerosis
  Journal ArticleHighNicholas R, Chataway J2009-01-01T00:00:00.000000Z

Frequently Asked Questions